Specialist Women and Children’s Health Pharmaceutical Company in China

GC-Rise’s mission is to improve women and children’s healthcare in China through innovation. The company has 2 lead drug products in the Chinese market; Remifemin as an alternative to HRT and Esberitox for immune support as well as a portfolio of synergistic products. GC-Rise offers a unique commercial platform to access family health in China.


A strategic partner

GC-Rise offers western partners unique access to this fast growing market by helping companies build a successful presence in China through policy interpretation, public affairs management, local registration, running of clinical trials, pricing, distribution to market promotion, brand-building and patient education. Through this GC-Rise provides novel and safe products for Chinese patients. The company has a number of follow-on products in the pipeline for launch in 2015+.

Recognition

The Company was listed in the top 50 fast-growing companies in China by Deloitte for two consecutive years and was the only pharmaceutical enterprise to be recognized.


www.gc-rise.com